Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT05696626
- Locations
- 🇺🇸
Mayo Clinic - Phoenix, Phoenix, Arizona, United States
🇺🇸University of Arizona - Cancer Center, Tucson, Arizona, United States
🇺🇸Providence Medical Foundation - Santa Rosa, CA, Santa Rosa, California, United States
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04432454
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB) - Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸Compassionate Cancer Care Med Group - Clinic Aid USA - Fountain Valley, Fountain Valley, California, United States
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03781063
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Yuma Regional Medical Center (JIT), Yuma, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer, Duarte, California, United States
News
Lasofoxifene Shows Promise in Early Breast Cancer Treatment, I-SPY 2 Trial Data Reveal
Lasofoxifene demonstrates a strong tolerability profile and promising Ki67 suppression in a Phase 2 study, supporting further exploration in the neoadjuvant setting.